We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

4 hedge funds and large institutions have $25K invested in NeuroSense Therapeutics Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

1.22% less ownership

Funds ownership: 2% → 0.78% (-1.2%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

75% less capital invested

Capital invested by funds: $98.9K → $25K (-$73.9K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$139
2
CS
Clear Street
New York
+$23

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$36.4K
2
Citadel Advisors
Citadel Advisors
Florida
-$4.29K
3
WAM
Warberg Asset Management
Illinois
-$2.16K

NRSNW Hedge Fund Activity: Q2 2024 in Review

4 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2024, worth a combined $25K — down 75% from $98.9K a quarter earlier.

Fund positioning in NRSNW was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $139. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $36.4K sold.

  • 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $25K of NeuroSense Therapeutics Warrant stock for Q2 2024, down 75% quarter-over-quarter.
  • 1 fund opened new NeuroSense Therapeutics Warrant positions in Q2 2024 and 1 closed out, a net change of 0 holders.
  • The largest NeuroSense Therapeutics Warrant buyer in Q2 2024 was UBS Group, an estimated $139 added.
  • The largest NeuroSense Therapeutics Warrant seller in Q2 2024 was Hudson Bay Capital Management, an estimated $36.4K sold.

Based on aggregated 13F filings for Q2 2024.